Know Your Number Aggregate Report Single Analysis Compared to National Averages

Similar documents
Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Screening Results. Juniata College. Juniata College. Screening Results. October 11, October 12, 2016

Statistical Fact Sheet Populations

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

Client Report Screening Program Results For: Missouri Western State University October 28, 2013

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

2017 Employee Wellness Health Assessment Report

Primary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group

Mississippi Stroke Systems of Care

Cardiovascular Risk Assessment and Management Making a Difference

Epidemiologic Measure of Association

Your health is a crucial aspect of your life. That s why the Yakima Heart Center offers this booklet; to help you identify the numbers that affect

Depok-Indonesia STEPS Survey 2003

Why Screen at 23? What can YOU do?

Director, Employee Health & Productivity. Coordinator, Employee Health & Productivity

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

MOLINA HEALTHCARE OF CALIFORNIA

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Integrated Health/Person Centered Health Home Austin Travis County Integral Care

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Test5, Here is Your My5 to Health Profile with Metabolic Syndrome Insight

DIABETES. A growing problem

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Journal of the American College of Cardiology Vol. 48, No. 2, by the American College of Cardiology Foundation ISSN /06/$32.

2013 Hypertension Measure Group Patient Visit Form

Implications of The LookAHEAD Trial: Is Weight Loss Beneficial for Patients with Diabetes?

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

Supplementary Online Content

A n aly tical m e t h o d s

Supplementary Online Content

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 The Metabolic Syndrome: Is It a Valid Concept?

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

Put your Heart before your Head

CARE PATHWAYS. Allyson Ashley

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

KEEP 2.0 Annual Data Report Chapter Five

Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms

Metabolic Syndrome and Workplace Outcome

Established Risk Factors for Coronary Heart Disease (CHD)

Supplementary Online Content

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Health Outcomes in the SSHVS Population Study. Loretta R Cain, MPH, PhD The University of Chicago

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Heart Health. Team Member Workbook Session 1 LEARN IDENTIFY ACT. Learn about HTHU Level 3 and the point system

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Guidelines on cardiovascular risk assessment and management

The Metabolic Syndrome: Is It A Valid Concept? YES

CARDIOVASCULAR HEALTH

What s New in Bariatric Surgery?

Report Operation Heart to Heart

Clinical Recommendations: Patients with Periodontitis

Your Name & Phone Number Here! Longevity Index

The Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Health Score SM Member Guide

Cleveland Clinic Heart Health Survey

Section 03: Pre Exercise Evaluations and Risk Factor Assessment

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE General practice Indicators for the NICE menu

Stroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital

Chapter 18. Diet and Health

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

KEEP 2009 Summary Figures

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

H e alth his to r y. Chapter 3 Health history. s29

Vascular Diseases. Overview: Selected Slides

Batch Upload Instructions

2010 ADA Guidelines: 1. Diagnostic Criteria for DM 2. Categories of increased risk of DM. Gerti Tashko, M.D. DM Journal Club 1/21/2010

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Diabetes, Diet and SMI: How can we make a difference?

Frequency of Metabolic Syndrome on Diabetes Mellitus Patients in Surabaya

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Rick Fox M.A Health and Wellness Specialist

«Πατσζαρκία και Καρδιαγγειακή Νόζος»

Supplementary Online Content

Cardiovascular Complications in Diabetes

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

KEEP Summary Figures S40. Am J Kidney Dis. 2012;59(3)(suppl 2):S40-S64

Objectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015

The Effects of Moderate Intensity Exercise on Lipoprotein-Lipid Profiles of Haramaya University Community

Myths, Heart Disease and the Latino Population. Maria T. Vivaldi MD MGH Women s Heart Health Program. Hispanics constitute 16.3 % of US population!

Text-based Document. Predicting Factors of Body Fat of Metabolic Syndrome Persons. Downloaded 13-May :51:47.

The National Diabetes Prevention Program in Washington State March 2012

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Understanding the metabolic syndrome

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

LEPTIN AS A NOVEL PREDICTOR OF DEPRESSION IN PATIENTS WITH THE METABOLIC SYNDROME

The Guidelines Guide: Routine Adult Screening Created March 2009 by Alana Benjamin, MD Last updated: June 29 th, 2010

Session 21: Heart Health

WIN UTILIZATION REPORT 7/1/2010 TO 6/30/2011

Association between Raised Blood Pressure and Dysglycemia in Hong Kong Chinese

NOT-FED Study New Obesity Treatment- Fasting, Exercise, Diet

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

ASSeSSing the risk of fatal cardiovascular disease

An Overview on Cardiovascular Risks Definitions by Using Survival Analysis Techniques-Tehran Lipid and Glucose Study: 13-Year Follow-Up Outcomes

Transcription:

Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2

Page 2 Study Population Demographics Gender Distribution Gender Number % Male 392 17.5% Female 1850 82.5% 2242 10% Male Female Age Distribution Age Number % 21-30 399 17.8% 31-40 589 26.3% 41-50 731 32.6% 51-60 455 20.3% 61-70 65 2.9% 71-80 3 0.1% >80 0 % 2242 10% 800 700 600 500 400 300 200 100 0 21-30 31-40 41-50 51-60 61-70 71-80 >80 Ethnicity Distribution Race Number % White 1434 64.0% Black 619 27.6% Asian 29 1.3% Hispanic 69 3.1% Others 91 4.1% 2242 10% White Black Asian Hispanic Others

Page 3 Health Status and Risk Factor Profile: Comparisons with National s Clinical Measures with Yes/No Values Number of Percentage National individuals %* ** Diagnosed (self reported) diseases Coronary Heart Disease 31 1.4% 3.6% Stroke 16 0.7% 1.5% Other Cardiovascular Diseases 21 0.9% 5.6% Heart Failure 13 0.6% 1.3% Diabetes 175 7.8% 4.8% On antihypertensive medication 549 24.5% 13.8% On lipid lowering medication 326 14.5% 6.3% Physical exercise level 1148 51.2% 21.6% Moderate 888 39.6% 46.4% 206 9.2% 32.1% Current smoking 278 12.4% 27.3% Overweight (BMI 25.0-29.9 kg/m2) 672 3% 29.0% Obesity (BMI>=30 kg/m2) 1015 45.3% 32.4% waist (male>40 inch, female>35 inch) 888 39.6% 50.5% Prehypertension (>=120/80 and <140/90 mmhg) 1036 46.2% 33.4% Hypertension (>=140/90 mmhg) 495 22.1% 14.6% Metabolic syndrome *** 637 28.4% 25.9% cholesterol>=200 mg/dl 709 31.6% 48.2% HDL (<40 mg/dl) 464 20.7% 18.6% LDL>=130 mg/dl 581 25.9% 38.6% LDL>=ATP III suggested goal 393 17.5% 24.8% Triglyceride>=150 mg/dl 465 20.7% 27.1% Undiagnosed diabetes (glucose>=126 mg/dl) 36 1.6% 1.4% Prediabetes (100<=glucose<126 mg/dl) 308 13.7% 14.2% Clinical Measures with Numerical Values Population Population National Mean SD**** Weight (lbs) 186.0 46.8 169.4 BMI (kg/m2) 30.3 7.2 28.2 Waist (inch) 35.3 6.7 36.6 Systolic blood pressure (mmhg) 123.5 15.5 119.2 Diastolic blood pressure (mmhg) 80.1 9.8 72.6 cholesterol (mg/dl) 185.1 36.2 200.7 HDL cholesterol (mg/dl) 51.4 14.7 52.4 LDL cholesterol (mg/dl) 111.7 31.8 122.9 Triglyceride (mg/dl) 112.6 82.4 130.9 Fasting glucose (mg/dl) 94.2 22.8 92.7 * Numbers in red indicate that the population may be less healthy than the National. ** The National is derived from the NHANES1999-2000 population and it is weighted by the age and gender distribution of the study population. In other words, the National is the average value among a national sample that have the same age and gender distribution as the study population. *** Metabolic syndrome is diagnosed based on the ATP III guideline criteria. **** SD stands for standard deviation.

Page 4 Health Status and Risk Factor Profile: Comparisons with National s (continued) Females Clinical Measures with Yes/No Values Number of Percentage National individuals % Diagnosed (self reported) diseases Coronary Heart Disease 15 0.8% 3.0% Stroke 12 0.6% 1.4% Other Cardiovascular Diseases 13 0.7% 5.3% Heart Failure 11 0.6% 1.1% Diabetes 145 7.8% 4.6% On antihypertensive medication 454 24.5% 13.9% On lipid lowering medication 241 13.0% 5.9% Physical exercise level 963 52.1% 22.8% Moderate 731 39.5% 47.1% 156 8.4% 3% Current smoking 227 12.3% 25.9% Overweight (BMI 25.0-29.9 kg/m2) 505 27.3% 26.7% Obesity (BMI>=30 kg/m2) 859 46.4% 33.6% waist (male>40 inch, female>35 inch) 783 42.3% 53.5% Prehypertension (>=120/80 and <140/90 mmhg) 821 44.4% 30.5% Hypertension (>=140/90 mmhg) 379 20.5% 14.0% Metabolic syndrome 493 26.6% 26.0% cholesterol>=200 mg/dl 588 31.8% 47.3% HDL (<40 mg/dl) 273 14.8% 15.0% LDL>=130 mg/dl 472 25.5% 36.9% LDL>=ATP III suggested goal 306 16.5% 22.5% Triglyceride>=150 mg/dl 335 18.1% 25.3% Undiagnosed diabetes (glucose>=126 mg/dl) 27 1.5% 1.3% Prediabetes (100<=glucose<126 mg/dl) 231 12.5% 12.7% Clinical Measures with Numerical Values Population Population National Mean SD Weight (lbs) 181.5 46.8 165.1 BMI (kg/m2) 30.5 7.5 28.3 Waist (inch) 34.7 6.6 36.1 Systolic blood pressure (mmhg) 122.0 15.2 118.3 Diastolic blood pressure (mmhg) 79.6 9.8 71.9 cholesterol (mg/dl) 185.7 35.7 199.9 HDL cholesterol (mg/dl) 53.4 14.6 53.8 LDL cholesterol (mg/dl) 111.4 31.5 121.6 Triglyceride (mg/dl) 105.1 71.6 125.6 Fasting glucose (mg/dl) 93.7 22.6 91.8

Page 5 Health Status and Risk Factor Profile: Comparisons with National s (continued) Males Clinical Measures with Yes/No Values Number of Percentage National individuals % Diagnosed (self reported) diseases Coronary Heart Disease 16 4.1% 6.4% Stroke 4 1.0% 1.7% Other Cardiovascular Diseases 8 2.0% 7.2% Heart Failure 2 0.5% 2.0% Diabetes 30 7.7% 5.7% On antihypertensive medication 95 24.2% 13.5% On lipid lowering medication 85 21.7% 8.3% Physical exercise level 185 47.2% 15.6% Moderate 157 40.1% 42.7% 50 12.8% 41.7% Current smoking 51 13.0% 34.2% Overweight (BMI 25.0-29.9 kg/m2) 167 42.6% 40.1% Obesity (BMI>=30 kg/m2) 156 39.8% 27.1% waist (male>40 inch, female>35 inch) 105 26.8% 36.4% Prehypertension (>=120/80 and <140/90 mmhg) 215 54.8% 47.5% Hypertension (>=140/90 mmhg) 116 29.6% 17.2% Metabolic syndrome 144 36.7% 25.4% cholesterol>=200 mg/dl 121 30.9% 52.5% HDL (<40 mg/dl) 191 48.7% 35.9% LDL>=130 mg/dl 109 27.8% 46.8% LDL>=ATP III suggested goal 87 22.2% 36.1% Triglyceride>=150 mg/dl 130 33.2% 36.0% Undiagnosed diabetes (glucose>=126 mg/dl) 9 2.3% 1.7% Prediabetes (100<=glucose<126 mg/dl) 77 19.6% 21.3% Clinical Measures with Numerical Values Population Population National Mean SD Weight (lbs) 207.3 40.8 190.1 BMI (kg/m2) 29.6 5.7 27.8 Waist (inch) 38.1 6.1 38.9 Systolic blood pressure (mmhg) 130.1 14.9 123.2 Diastolic blood pressure (mmhg) 82.5 9.3 75.9 cholesterol (mg/dl) 182.3 38.6 204.8 HDL cholesterol (mg/dl) 41.7 11.3 46.0 LDL cholesterol (mg/dl) 113.2 33.3 128.9 Triglyceride (mg/dl) 147.8 114.9 155.8 Fasting glucose (mg/dl) 96.7 23.8 96.8

Page 6 Distribution of Disease Risks in Population By Percentiles Type 2 Diabetes N*= 2031 Coronary Heart Disease N= 2242 Below Below 21% 20% 20% 19% 21% 20% 24% 24% 20% 14% 25% 25% 20% 20% 15% 15% 10% 10% 5% 5% 0% Below 0% Below Stroke N= 2226 Heart Failure N= 1242 Below Below 34% 21% 19% 15% 10% 29% 26% 18% 14% 13% 35% 30% 25% 20% 15% 10% 5% 0% Below 30% 25% 20% 15% 10% 5% 0% Below Notes: Disease risk is classifed by risk percentile of the following groups: <20th percentile Moderate >=20th & <40th percentile >=40th & <60th percentile Moderate >=60th &< 80th percentile >=80th percentile Percentile is age and gender specific. H *N refers to the number of people who had a prediction for the specific disease. No data for COPD and lung cancer because those models were only run for smokers.

Page 7 Study Population Projected & Cases of Disease Onset within Next Five Years and Comparisons* with National s Type 2 Diabetes Coronary Heart Disease ** *** Study Population 78.8 65.6 Study Population 41.3 26.4 National **** 72.7 61.3 National 43.0 29.8 8 6 4 2 ** *** 5 4 3 2 1 Study Population National **** Study Population National Stroke Heart Failure Study Population 26.8 20.6 Study Population 16.6 6.1 National 10.8 8.0 National 8.1 2.8 3 25.0 2 15.0 1 5.0 Study Population National 2 15.0 1 5.0 Study Population National * The study population may be less healthy than the National when numbers are shown in red. ** cases are the projected number of new cases in the next 5 years in the study population. *** cases are the cases that can be avoided in the next 5 years, if all modifiable risk factors are brought within the normal range. **** The National is derived from the NHANES1999-2000 population and it is weighted by the age and gender distribution of the study population. In other words, the National is the average value among a national sample that have the same age and gender distribution as the study population.

Page 8 Study Population Projected & Cases of Disease Onset within Next Five Years and Comparisons with National s (continued) COPD Study Population 12.8 5.3 National 17.3 6.8 2 15.0 1 5.0 Study Population National Lung Cancer Study Population 0.7 0.5 National 2.7 1.4 3.0 2.5 2.0 1.5 1.0 0.5 Study Population National

Date of Single Report: 8/16/2007 Page 9 Cases* of Disease Onset by Risk Factor Rist Factors Diabetes CHD Stroke CHF COPD Lung Cancer** Weight 45.6 4.9 9.8 5.1 65.3 Blood Pressure 2.8 6.0 5.5 1.1 15.3 Exercise 7.3 4.2 4.3 0.2 15.9 Smoking 3.1 2.8 1.1 5.3 0.3 12.6 Cholesterol 1.3 7.7 8.9 Glucose 5.6 5.6 Aspirin 0.9 0.9 Cases 65.6 26.4 20.6 6.1 5.3 0.5 124.5 The spaces in the table refer to a risk factor that does not contribute to the risk of that disease. 70 60 50 40 30 20 10 Diabetes CHD Stroke CHF COPD Lung Cancer** 0 70 60 50 40 30 20 10 0 Weight Blood Pressure Exercise Smoking Cholesterol Glucose Aspirin * cases are the cases that can be avoided in the next 5 years, if each modifiable risk factor is brought within the normal range. ** Even though almost all of lung cancer cases are attributed to smoking, quitting smoking can only reduce a small portion of lung cancer risk within the next 5 years. The impact of quitting smoking would be much higher in 10 to 20 years.

Page 10 Extrapolation to Population * Projected & Cases of Disease Onset within Next Five Years and Comparisons** with National s Population: N= 3000 Type 2 Diabetes Coronary Heart Disease **** ***** Population 105.4 87.7 Population 55.2 35.3 National *** 109.3 92.0 National 57.5 39.9 12 10 8 6 4 2 **** ***** 6 5 4 3 2 1 Population National *** Population National Stroke Heart Failure Population 35.9 27.6 Population 22.2 8.2 National 14.6 10.8 National 10.9 3.8 4 3 2 1 Population National 25.0 2 15.0 1 5.0 Population National * population is the population that the study population represents. ** The total population may be less healthy than the National when numbers are shown in red. *** The National is derived from the NHANES1999-2000 population and it is weighted by the age and gender distribution of the total population. In other words, the National is the average value among a national sample that have the same age and gender distribution as the total population. **** cases are the projected number of new cases in the next 5 years in the total population. ***** cases are the cases that can be avoided in the next 5 years in the total population, if all modifiable risk factors are brought within the normal range.

Page 11 Extrapolation to Population * Cases** of Disease Onset by Risk Factor Population: N= 3000 Risk Factors Diabetes CHD Stroke CHF COPD Lung Cancer*** Weight 61.0 6.6 13.1 6.8 87.4 Blood Pressure 3.7 8.0 7.3 1.4 20.4 Exercise 9.7 5.6 5.7 0.3 21.3 Smoking 4.1 3.7 1.5 7.1 0.4 16.8 Cholesterol 1.7 10.3 11.9 Glucose 7.5 7.5 Aspirin 1.2 1.2 Cases 87.7 35.3 27.6 8.2 7.1 0.6 166.7 The spaces in the table refer to a risk factor that does not contribute to the risk of that disease. 9 Diabetes 8 CHD 7 6 Stroke 5 4 CHF 3 COPD 2 1 Lung Cancer*** 9 8 7 6 5 4 3 2 1 Weight Blood Pressure Exercise Smoking Cholesterol Glucose Aspirin * population is the population that the study population represents. ** cases are the cases that can be avoided in the next 5 years, if each modifiable risk factor is brought within the normal range. *** Even though almost all of lung cancer cases are attributed to smoking, quitting smoking can only reduce a small portion of lung cancer risk within the next 5 years. The impact of quitting smoking would be much higher in 10 to 20 years.

Page 12 Predicted Five-year Cost * of Future Chronic Disease Onset Comparisons** with National s Study Population*** Study Population N= 2242 Diseases Study Population National Predicted Predicted Predicted Predicted Cost Cost Cost Cost Type 2 Diabetes $2,147,752 $1,788,338 $1,983,937 $1,670,801 Coronary Heart Disease $989,580 $633,155 $1,030,986 $715,525 Stroke $751,198 $577,651 $302,177 $222,642 Heart Failure $265,105 $97,970 $129,098 $44,505 COPD $104,351 $43,588 $141,072 $55,495 Lung Cancer $51,157 $31,428 $181,924 $98,578 All Diseases $4,309,142 $3,172,128 $3,769,194 $2,807,546 Extrapolation to Population**** Population N= 3000 Diseases Population National Predicted Predicted Predicted Predicted Cost Cost Cost Cost Type 2 Diabetes $2,873,888 $2,392,959 $2,654,689 $2,235,684 Coronary Heart Disease $1,324,148 $847,219 $1,379,553 $957,438 Stroke $1,005,171 $772,950 $404,340 $297,915 Heart Failure $354,734 $131,092 $172,745 $59,551 COPD $139,631 $58,324 $188,767 $74,258 Lung Cancer $68,452 $42,053 $243,431 $131,906 All Diseases $5,766,024 $4,244,596 $5,043,525 $3,756,752 * The formula used to calculate probable cost is: probability of disease onset (KYN) x 2.5 years x annual cost of disease. ** The population may have more expenses for the specific disease compared with the National when it is shown in red. *** Study population is the population who participated in Know Your Number. **** population is the population that the study population represents. The annual cost for type 2 diabetes was $10,909; CHD was $9,595; stroke was $11,196; CHF was $6,385; COPD was $3,263; lung cancer was $27,324 per patient year. The costs included direct and indirect medical costs associated with occurrence of each disease. They were calculated using the most current annual costs based on national averages documented by the American Heart Association, the American Diabetes Association, the American Lung Association and National Cancer Institute.